Kisqali, a New CDK4/CDK6 Inhibitor, Approved as First-Line Therapy for HR-Positive, HER2-Negative Advanced Breast Cancer
Extending aromatase inhibitor therapy with letrozole for an additional 5 years beyond standard treatment with letrozole improved disease-free survival (DFS) and reduced the rate of new contralateral breast cancer in postmenopausal women with estrogen receptor (ER)-positive breast cancer. Prolonged letrozole did not improve overall survival. These were the main findings of the large MA.17R trial, which were presented at the plenary session at ASCO 2016.
The addition of lapatinib (Tykerb) to trastuzumab (Herceptin) to create dual HER2 blockade was no better than trastuzumab alone in the adjuvant treatment of patients with HER2 breast cancer in the global phase 3 ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) trial, reported Martine J. Piccart-Gebhart, MD, PhD, Chair, Breast International Group, Brussels, Belgium, at a plenary session at ASCO 2014.
In patients with breast cancer and bone metastasis, less frequent infusion of zoledronic acid was as effective as the standard monthly dose in the randomized OPTIMIZE-2 study.
Adjuvant exemestane is more effective at preventing breast cancer recurrences than tamoxifen when given with ovarian function suppression (OFS) in young women with hormone receptor–positive early breast cancer, reported Olivia Pagani, MD, Clinical Director, Breast Unit, Oncology Institute of Southern Switzerland, Bellinzona, during ASCO 2014.
New Data Confirm Benefits of 10 Years Tamoxifen versus 5 Years in Patients with ER-Positive Breast Cancer
Chicago, IL—Updated data confirm that 10 years of adjuvant tamoxifen is superior to 5 years in reducing the rates of late recurrence and death in women with estrogen receptor (ER)-positive breast cancer, reported Richard G. Gray, MA, MSc, Professor of Medical Statistics, University of Oxford, United Kingdom.
Chicago, IL—The media darling at ASCO 2012 was a novel agent some called a “smart bomb,” because of its highly targeted and potent effect that spares surrounding healthy tissue.
Trastuzumab emtansine, better known as T-DM1, the antibody-drug conjugate linking trastuzumab to a cytotoxic agent, delivers its punch directly into the tumor of patients with HER2-positive metastatic breast cancer, and this agent is associated with little toxicity. T-DM1 is one of an entirely new class of agents that could have a major impact on the disease.
Chicago, IL—Adverse events related to chemotherapy for metastatic breast cancer lead to a substantial economic burden that is primarily explained by increased inpatient, outpatient, and pharmacy costs, said lead investigator Sara A. Hurvitz, MD, Director of the Oncology Breast Cancer Program at University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center and Assistant Clinical Professor at UCLA School of Medicine, who presented an economic analysis at ASCO 2012.
Until recently, women at risk for breast cancer have had 2 pharmacologic options to reduce their risk— tamoxifen (Nolvadex) and raloxifene (Evista). Now a third option has been shown effective, the aromatase inhib - itor exemestane (Aromasin).
In the National Cancer Institute of Canada Clinical Trials Group MA.20 trial, regional irradiation to the lymph nodes (RNI) added to whole brain irradiation (WBI) improved disease-free survival (DFS), with a trend toward improved overall survival (OS), reported Timothy Whelan, MD, of McMaster University and the Juravinski Cancer Centre in Hamilton, Ontario.
Results 1 - 10 of 10